Abstract
Background: We used B16-F1O (B16) melanoma tumor cells and syngeneic C57BL/6 (B6) mice as a study model for pulmonary metastases, to better understand whether or not there exist differences in tumorigenicity and in the effectiveness of immunotherapy as a function of host age (1-, 3-, 12- and 24-month-old). Methods: Intravenous injection of B16 melanoma cells were administered to B6 mice of different ages with/without interleukin (IL)-2 and IL-12 daily treatment. Tumor growth, splenocyte function, serum cytokines (IL-10, interferon-γ, vascular endothelial growth factor) and survival were compared. Results: The study showed that, without IL-2 and IL-12 treatment, middle-aged mice suffering from pulmonary metastases had fewer pulmonary metastases and better survival than younger mice suffering from pulmonary metastases. Three days' IL-2 plus IL-12 treatment could not prolong mice survival, but prolonged treatment significantly improved the survival of both the younger and older tumor-bearing mice, especially the older mice, despite the fact that the younger mice had a better serum cytokine and splenocyte cellular immune response to cytokine treatment. Conclusion: The young B6 mice that suffered from B16 pulmonary metastases had a poorer prognosis than the middle-aged mice. Short-term IL-2 plus IL-12 treatment is ineffective in prolonging survival, and a longer duration of treatment is needed. This kind of immunotherapy was effective in both the young and middle-aged mice, but it was more effective in the middle-aged mice.
| Original language | English |
|---|---|
| Pages (from-to) | 94-102 |
| Number of pages | 9 |
| Journal | Journal of the Chinese Medical Association |
| Volume | 70 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jan 1 2007 |
| Externally published | Yes |
Fingerprint
Keywords
- Age
- Immunotherapy
- Pulmonary metastases
ASJC Scopus subject areas
- Medicine(all)
Cite this
Effect of age on pulmonary metastases and immunotherapy in young and middle-aged mice. / Chen, Yuh Min; Wang, Pi Sheng; Liu, Jacqueline Ming; Hsieh, Yi Lin; Tsai, Chun Ming; Perng, Reury Perng; Whang-Peng, Jacqueline.
In: Journal of the Chinese Medical Association, Vol. 70, No. 3, 01.01.2007, p. 94-102.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of age on pulmonary metastases and immunotherapy in young and middle-aged mice
AU - Chen, Yuh Min
AU - Wang, Pi Sheng
AU - Liu, Jacqueline Ming
AU - Hsieh, Yi Lin
AU - Tsai, Chun Ming
AU - Perng, Reury Perng
AU - Whang-Peng, Jacqueline
PY - 2007/1/1
Y1 - 2007/1/1
N2 - Background: We used B16-F1O (B16) melanoma tumor cells and syngeneic C57BL/6 (B6) mice as a study model for pulmonary metastases, to better understand whether or not there exist differences in tumorigenicity and in the effectiveness of immunotherapy as a function of host age (1-, 3-, 12- and 24-month-old). Methods: Intravenous injection of B16 melanoma cells were administered to B6 mice of different ages with/without interleukin (IL)-2 and IL-12 daily treatment. Tumor growth, splenocyte function, serum cytokines (IL-10, interferon-γ, vascular endothelial growth factor) and survival were compared. Results: The study showed that, without IL-2 and IL-12 treatment, middle-aged mice suffering from pulmonary metastases had fewer pulmonary metastases and better survival than younger mice suffering from pulmonary metastases. Three days' IL-2 plus IL-12 treatment could not prolong mice survival, but prolonged treatment significantly improved the survival of both the younger and older tumor-bearing mice, especially the older mice, despite the fact that the younger mice had a better serum cytokine and splenocyte cellular immune response to cytokine treatment. Conclusion: The young B6 mice that suffered from B16 pulmonary metastases had a poorer prognosis than the middle-aged mice. Short-term IL-2 plus IL-12 treatment is ineffective in prolonging survival, and a longer duration of treatment is needed. This kind of immunotherapy was effective in both the young and middle-aged mice, but it was more effective in the middle-aged mice.
AB - Background: We used B16-F1O (B16) melanoma tumor cells and syngeneic C57BL/6 (B6) mice as a study model for pulmonary metastases, to better understand whether or not there exist differences in tumorigenicity and in the effectiveness of immunotherapy as a function of host age (1-, 3-, 12- and 24-month-old). Methods: Intravenous injection of B16 melanoma cells were administered to B6 mice of different ages with/without interleukin (IL)-2 and IL-12 daily treatment. Tumor growth, splenocyte function, serum cytokines (IL-10, interferon-γ, vascular endothelial growth factor) and survival were compared. Results: The study showed that, without IL-2 and IL-12 treatment, middle-aged mice suffering from pulmonary metastases had fewer pulmonary metastases and better survival than younger mice suffering from pulmonary metastases. Three days' IL-2 plus IL-12 treatment could not prolong mice survival, but prolonged treatment significantly improved the survival of both the younger and older tumor-bearing mice, especially the older mice, despite the fact that the younger mice had a better serum cytokine and splenocyte cellular immune response to cytokine treatment. Conclusion: The young B6 mice that suffered from B16 pulmonary metastases had a poorer prognosis than the middle-aged mice. Short-term IL-2 plus IL-12 treatment is ineffective in prolonging survival, and a longer duration of treatment is needed. This kind of immunotherapy was effective in both the young and middle-aged mice, but it was more effective in the middle-aged mice.
KW - Age
KW - Immunotherapy
KW - Pulmonary metastases
UR - http://www.scopus.com/inward/record.url?scp=34247382458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247382458&partnerID=8YFLogxK
U2 - 10.1016/S1726-4901(09)70338-7
DO - 10.1016/S1726-4901(09)70338-7
M3 - Article
C2 - 17389153
AN - SCOPUS:34247382458
VL - 70
SP - 94
EP - 102
JO - Journal of the Chinese Medical Association
JF - Journal of the Chinese Medical Association
SN - 1726-4901
IS - 3
ER -